Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 88, Issue 1, 2008, Pages 104-110

  Okamura, Atsuo ^a   Yamamori, Motohiro ^b   Shimoyama, Manabu ^a   Kawano, Yuko ^a   Kawano, Hiroki ^a   Kawamori, Yuriko ^a   Nishikawa, Shinichiro ^a   Minagawa, Kentaro ^a   Yakushijin, Kimikazu ^a   Katayama, Yoshio ^a   Sakaeda, Toshiyuki ^b   Hirai, Midori ^b   Matsui, Toshimitsu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute GVHD; Dose escalation; Dosing interval; Engraftment; MMF; Pharmacokinetics

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; JAPANESE; MALE; OUTCOME ASSESSMENT; VIRUS INFECTION; VOMITING;

ACUTE DISEASE; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 56749163477     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0093-4     Document Type: Article

References (26)

1. WD Shlomchik MS Couzens CB Tang J McNiff ME Robert J Liu 1999 Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science. 285 412 5
2. FR Appelbaum 2001 Haematopoietic cell transplantation as immunotherapy Nature. 411 385 9
3. R Storb HJ Deeg J Whitehead F Appelbaum P Beatty W Bensinger 1986 Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia N Engl J Med. 314 729 35
4. GB Vogelsang S Arai 2001 Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings Bone Marrow Transplant. 27 1255 62
5. R Zeiser R Marks H Bertz J Finke 2004 Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies Ann Hematol. 83 551 65
6. A Bacigalupo 2007 Management of acute graft-versus-host disease Br J Haematol. 137 87 98
7. B Bolwell R Sobecks B Pohlman S Andresen L Rybicki E Kuczkowski 2004 A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation Bone Marrow Transplant. 34 621 5
8. F Neumann T Graef C Tapprich M Vaupel U Steidl U Germing 2005 Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings Bone Marrow Transplant. 35 1089 93
9. Y Kawamori K Yakushijin A Okamura S Nishikawa K Minagawa M Shimoyama 2007 Successful engraftment in reduced-intensity cord blood transplantation (CBT) as a salvage therapy for graft failure after primary CBT in adults Transplantation. 83 1281 2
10. RE Bullingham AJ Nicholls BR Kamm 1998 Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet. 34 429 455
11. RM van Hest JK Doorduijn BC de Winter JJ Cornelissen AG Vulto M Oellerich 2007 Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients Ther Drug Monit. 29 353 60
12. J Ng J Rogosheske J Barker D Weisdorf PA Jacobson 2006 A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT) Ther Drug Monit. 28 394 401
13. LM Shaw DW Holt M Oellerich B Meiser T van Gelder 2001 Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion Ther Drug Monit. 23 305 15
14. I Osunkwo O Bessmertny L Harrison YK Cheung C Van de Ven G del Toro 2004 A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients Biol Blood Marrow Transplant. 10 246 58
15. P Jacobson J Rogosheske JN Barker K Green J Ng D Weisdorf 2005 Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation Clin Pharmacol Ther. 78 486 500
16. L Giaccone JS McCune MB Maris TA Gooley BM Sandmaier JT Slattery 2005 Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation Blood. 106 4381 8
17. MB Maris BM Sandmaier BE Storer DG Maloney JA Shizuru E Agura 2006 Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing Biol Blood Marrow Transplant. 12 454 65
18. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows 1995 1994 Consensus conference on acute GVHD grading Bone Marrow Transplant. 15 825 8
19. T Van Gelder J Klupp MJ Barten U Christians RE Morris 2001 Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure J Heart Lung Transplant. 20 160 1
20. RA Nash L Johnston P Parker JS McCune B Storer JT Slattery 2005 A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant. 11 495 505
21. R Storb C Yu JL Wagner HJ Deeg RA Nash HP Kiem 1997 Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood. 89 3048 54
22. PA McSweeney D Niederwieser JA Shizuru BM Sandmaier AJ Molina DG Maloney 2001 Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood. 97 3390 400
23. G Kobbe P Schneider M Aivado F Zohren D Schubert R Fenk 2002 Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning Exp Hematol. 30 1346 53
24. MG Kiehl K Schafer-Eckart M Kroger M Bornhauser N Basara IW Blau 2002 Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients Transplant Proc. 34 2922 4
25. M Bornhauser U Schuler G Porksen R Naumann G Geissler C Thiede 1999 Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation Transplantation. 67 499 504
26. Y Nieto N Patton T Hawkins R Spearing SI Bearman RB Jones 2006 Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation Biol Blood Marrow Transplant. 12 217 25